Stefanie Urlinger

Chief Scientific Officer • Cimeio Therapeutics

Stefanie Urlinger is Chief Scientific Officer at Cimeio Therapeutics, where she heads Research and Discovery. Stefanie has over 20 years of experience in large molecule engineering and development and has led antibody discovery efforts as well as the development of antibody platform technologies in different organizations, including MorphoSys, iOmx Therapeutics and Ridgeline Discovery. Stefanie has authored many scientific articles and is an inventor on over 60 granted patents. Stefanie earned her PhD from the Max-Planck-Institute for Biochemistry in Germany.

Also speaking

Frank Thielmann

Head Lean, Global Operational Excellence • Takeda

Antonin de Fougerolles

Chief Executive Officer • Evox Therapeutics

Jennifer Rabin

Specialist Leader, Next Gen Therapy Practice • Deloitte

Event Info


Sponsorship Opportunities Waiting List

Take a look at the sample attendee list for Advanced Therapies Europe 2023 here.


Find out more about partnering at Advanced Therapies Europe.